Drawing for ARMADA THERAPEUTICS

USPTO serial 88311979

ARMADA THERAPEUTICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
ENGEL, MICHAEL
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ARMADA THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

James DeZazzo

JAMES DEZAZZO LEADING BIOSCIENCES5800 ARMADA DRIVESUITE 210CARLSBAD, CA 92008

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical formulations and preparations to treat acute and chronic health conditions related to gastrointestinal, inflammatory, metabolic, endocrine, immunological, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, psychiatric, dermatological, and viral diseases and disorders; Pharmaceutical compositions in liquid form, namely, liquid compositions containing protease inhibitors, to treat health conditions, diseases, and disorders related to the gastrointestinal tract, gastrointestinal permeability, the gastrointestinal epithelial barrier, gastrointestinal inflammation, the gastrointestinal immune system, the microbiome, and the gut-brain axis; Pharmaceutical formulations and preparations to treat or prevent surgical complications and post-surgical complications; Pharmaceutical formulations and preparations to treat or prevent shock, namely, acute shock, cardiogenic shock, septic shock and hemorrhagic shock; Pharmaceutical formulations and preparations to treat or prevent gastrointestinal tract injuries, ileus, and adhesions; Pharmaceutical formulations and preparations to treat or prevent multi-organ failure; Pharmaceutical formulations and preparations to treat or prevent health conditions, diseases, and disorders related to intestinal permeability, the microbiome, and the gut-brain axisACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 16, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 16, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 13, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 18, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 18, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 29, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 10, 2019PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 7, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 7, 2019XAECEXAMINER'S AMENDMENT ENTERED—
May 7, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 7, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
May 7, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
May 3, 2019XAECEXAMINER'S AMENDMENT ENTERED—
May 3, 2019ALIEASSIGNED TO LIE—
May 3, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 3, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
May 3, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
May 3, 2019DOCKASSIGNED TO EXAMINER—
Mar 21, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 26, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance